The use of ciclosporin in paediatric inflammatory bowel disease: An Italian experience

A. Barabino, F. Torrente, E. Castellano, P. Gandullia, A. Calvi, S. Cucchiara, G. L. De'Angelis, M. Fontana, P. Lionetti, C. De Giacomo, A. Gissi

Research output: Contribution to journalArticlepeer-review


Aim: To asses the efficacy and safety of ciclosporin in a paediatric population with inflammatory bowel disease. Patients and methods: Twenty-three Italian children treated with ciclosporin were studied retrospectively. The indications for treatment were severe unresponsive colitis, chronic active colitis or severe fistulizing Crohn's disease. The treatment duration, follow-up and causes of drug discontinuation were assessed. Results: Sixteen patients were treated intravenously for a mean time of 10 ± 7 days (1-24 days) and 19 orally for a mean time of 133 days (17-660 days). The mean follow-up of all patients was 13.2 months. Ciclosporin was totally ineffective, being discontinued for surgery, in nine of 23 patients (39%); it was discontinued for partial response in three patients (13%). During treatment, clinical remission was achieved in eight children (35%) and maintained after drug withdrawal in four (17%). In severe unresponsive colitis, urgent colectomy was avoided in 12 (85%) of 14 patients who tolerated the drug. Side-effects appeared in six of 23 patients (26%), and three (13%) required ciclosporin to be discontinued due to neurotoxicity. Conclusions: Ciclosporin shows disappointing long-term results in the treatment of refractory inflammatory bowel disease, but can play an important role in preventing urgent surgery in unresponsive severe colitis. Severe side-effects can occur.

Original languageEnglish
Pages (from-to)1503-1507
Number of pages5
JournalAlimentary Pharmacology and Therapeutics
Issue number8
Publication statusPublished - Aug 2002

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'The use of ciclosporin in paediatric inflammatory bowel disease: An Italian experience'. Together they form a unique fingerprint.

Cite this